You are here

  • Home
  • Archive
  • Volume 24, Issue 2
  • Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression

Citation Tools

Article menu
Download PDFPDF
Basic Science
Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Secord AA, Teoh D, Jia J, et al
Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression
International Journal of Gynecologic Cancer 2014;24:218-225.